Origami Therapeutics, Inc.

Congratulations to Origami Therapeutics, Inc.. on their recent #SBIR Phase I award. Their project is entitled "Characterization of small molecules that lower mutant huntingtin protein as potential therapeutics for Huntington’s disease". Normal #huntingtin protein (HTT) is essential throughout the body and brain to regulate cell physiology. In patients with #Huntington’sdisease (#HD), mutant HTT (mHTT) folds abnormally, resulting in toxic mHTT fragments. Experimental procedures that lower mHTT have reversed disease symptoms in animal models of HD. However, clinical translation of treatments directed at this mechanism of action have stalled and is, in part, hypothesized to be due to nonselective lowering of both the essential HTT as well as mHTT. Origami Therapeutics has identified a small molecule, #ORI113, that prevents mHTT aggregation, and selectively lowers mHTT levels in assays employing HD patient-derived fibroblasts and iPSC-derived medium spiny neurons as well as the #YAC128 mouse model of HD. The efficacy and drug-like properties of twelve analogs of ORI-113 will be compared and lead compounds will undergo #pharmacokinetic and #brainexposure profiling following oral administration. The studies aim to identify a lead therapeutic drug candidate to move into Investigational New Drug Application studies. 

Join #SDEE for “Strategies for #Founders #Fundraising” on May 16, 5-7:30 pm at Green Acre Campus Point. Beth J Hoffman from Origami Therapeutics, Inc. will moderate an all-founder panel with Mauro Mileni of Abilita Therapeutics, Inc., Devon Cayer of om, and Philipp Baaske of NanoTemper Technologies. Register at https://lnkd.in/dYSYccRi Janelle Hunt Marilyn Ferrari Danielle Hayes Randy Schreckhise Taylor Moyer Ted Jacobs Jim Krenn Jiwu Wang R Scott Struthers Scott Thacher Kathrin Copley Lynda Groocock Lecya Tyaglo Richard Lin Ruo Steensma Martin Eglitis

Come support our women founders as they pitch in front of potential investors. Learn about their innovative solutions at our Galentine's Day event after the exclusive screening of Show Her The Money. 𝐒𝐭𝐚𝐫𝐭𝐮𝐩 𝐒𝐡𝐨𝐰𝐜𝐚𝐬𝐞 🔸Kiran Kumar - Timeless Biotech Timeless Biotech aims to predict menopause and improve the transition, with a broader goal of utilizing AI to customize hormonal treatments and supplements for women, addressing hormone imbalances affecting 80% of them. 🔸Hagit Leshem - GateKey GateKey is a medical device which offers a painless childbirth by activation of physiological mechanisms during labor. 🔸Cassia Connors, PE, MBA - Flok22 Flok22 facilitates immediate, geolocation-based networking at large events, allowing users to check in, filter connections, and connect in person, addressing a gap in existing conference apps. 🔸Joanna Shu - FreezeNit Inc. FreezeNit quickly kills head lice and nits using only cold CO2 gas, without messy creams, harmful pesticides, or prescriptions. 🔸Beth J Hoffman - Origami Therapeutics, Inc. Origami Therapeutics, a pre-clinical stage company located in San Diego, California, was founded on an innovative small molecule approach to functionally curing neurodegeneration, anticipating a development candidate nomination in Q1 2025. 🔸Melissa Krebs, Ph.D. - GelSana GelSana is developing novel highly elastic wound dressings which can stretch across or conform to any wound with proprietary polymer chemistry that inherently reduces inflammation and prevents infection and are capable of providing controlled drug release. 🔸Clair Purcell - Alcheme Bio Alcheme Bio allows cultivated food producers and those using precision fermented ingredients the ability to precisely adjust media and feedstock formulations to imbue foods with robust flavors, just like nature does. 🔸Carolyn Hamlet - ōku ōku Conscious Energy Gummy Snacks seamlessly blend indulgence with benefits by ingeniously addressing the pervasive concerns of energy dips and irresistible sweet temptations, while resonating with today's 'Conscious Consumer.' 🔸Katherine (Kate) Hillman - Veera Veera's mission is to offer postpartum mothers the care, ease, and peace of mind they deserve during the early stages of motherhood and breastfeeding. #sandiego #business #entrepreneurship #invest #sandiegobusiness

Join my esteemed colleagues, Russ Teichert, MBA, PhD (Scintillant Bioscience Founder and CEO), David Bearss Ph.D. (Halia Therapeutics, Inc. CEO), Andrea Mazzocchi, PhD (VP of Partnerships at Pathos and former Known Medicine CEO), and I on Wednesday, November 8th (4:00pm ET) for @Scintillant Biosciences’s first Talking Therapeutics virtual panel, “Visualizing the Present and Future: Imaging 2D Cell Culture and 3D Organoids for Therapeutics Discovery.” During this panel we will explore the latest advancements in cell imaging technologies, methodologies, and their applications in real-world therapeutics discovery.   A link to register is on the LinkedIn event page: https://lnkd.in/gW_hsmrV   Talking Therapeutics is a Scintillant Bioscience initiative that aims to bridge the gap between laboratory research and clinical outcomes. This virtual series assembles a panel of industry experts, researchers, and clinicians to discuss emerging trends, share insights, and tackle the most pressing challenges in therapeutics discovery and development today. Topics range from the latest targets, technologies, techniques, and trends. Tune in to Talking Therapeutics to gain actionable insights, discover novel approaches, and connect with a community that shares your passion for advancing medicine.